DUBLIN–(BUSINESS WIRE)–The “Biliary Tract Cancers (BTCs) – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of biliary tract cancer (BTC) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The biliary tract cancer market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted biliary tract cancer market Size from 2017 to 2030, segmented by seven major markets. The report also covers the current biliary tract cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
The disease epidemiology covered in the report provides historical and forecasted Biliary Tract Cancer epidemiology segmented as the total incident cases of biliary tract cancer, age-specific cases of biliary tract cancer, stage-specific cases of biliary tract cancer and mutation specific cases of biliary tract cancer. The report includes the incident scenario of Biliary Tract Cancer symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country-wise Biliary Tract Cancer Epidemiology
The epidemiology segment also provides the Biliary Tract Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total incident population of biliary tract cancer in the 7MM countries was estimated to be 70,111 cases in 2017.
Biliary Tract Cancer Drug Chapters
The drug chapter segment of the Biliary tract cancer report encloses the detailed analysis of biliary tract cancer marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II and Phase-I/II) pipeline drugs. It also helps to understand the biliary tract cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late-stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy. Few more aggressive surgical approaches and improved radiologic techniques have resulted in improved R0 (tumor-free margins) resection rates, but recurrence rates remain high.
Biliary Tract Cancer Market Outlook
The Biliary Tract Cancer market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Biliary Tract Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of biliary tract cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, biliary tract cancer market in the 7MM is expected to change in the study period 2017-2030.
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the biliary tract cancer market
- To understand the future market competition in the biliary tract cancer market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for biliary tract cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for biliary tract cancer market.
- To understand the future market competition in the biliary tract cancer market.
Companies Mentioned
- Agios Pharmaceuticals
- AstraZeneca
- Basilea PharmaceuticaL
- Bayer
- BeiGene
- Bristol-Myers Squibb
- Celgene
- Daiichi Sankyo
- Delcath Systems
- Eisai
- GlaxoSmithKline
- Hutchison Medipharma Limited
- Incyte Corporation
- Ipsen
- Janssen Pharmaceutical
- Karus Therapeutics
- KLUS Pharma
- Leap Therapeutics
- Lexicon Pharmaceuticals/TerSera Therapeutics
- Loxo Oncology/Bayer
- Merck Sharp & Dohme Corp.
- NuCana
- PCI biotech
- QED Therapeutics
- RedHill Biopharma
- Roche
- Syndax Pharmaceuticals
- Taiho Oncology
- Taiho Pharma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tqkgrr
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900